Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience

M. Molnár, Satheesh Nair, Orsolya Cseprekal, Masahiko Yazawa, Manish Talwar, Vasanthi Balaraman, Pradeep S.B. Podila, Valeria Mas, Daniel Maluf, Ryan A. Helmick, Luis Campos, Nosratollah Nezakatgoo, Corey Eymard, Peter Horton, Rajanshu Verma, Ann Holbrook Jenkins, Charlotte R. Handley, Heather S. Snyder, Carolyn Cummings, Uchenna A. AgbimBenedict Maliakkal, Sanjaya K. Satapathy, James D. Eason

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA–negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2, respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients.

Original languageEnglish
JournalAmerican Journal of Transplantation
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Kidney Transplantation
Hepatitis
Tissue Donors
Kidney
Antiviral Agents
RNA
Transplants
Therapeutics
Transaminases
African Americans
Observational Studies
Histology
Reference Values
Genotype
Safety
Antibodies
Liver
Infection

Keywords

  • clinical research/practice
  • hepatitis C
  • infection and infectious agents - viral
  • kidney (allograft) function/dysfunction
  • kidney transplantation/nephrology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients : Single center experience. / Molnár, M.; Nair, Satheesh; Cseprekal, Orsolya; Yazawa, Masahiko; Talwar, Manish; Balaraman, Vasanthi; Podila, Pradeep S.B.; Mas, Valeria; Maluf, Daniel; Helmick, Ryan A.; Campos, Luis; Nezakatgoo, Nosratollah; Eymard, Corey; Horton, Peter; Verma, Rajanshu; Jenkins, Ann Holbrook; Handley, Charlotte R.; Snyder, Heather S.; Cummings, Carolyn; Agbim, Uchenna A.; Maliakkal, Benedict; Satapathy, Sanjaya K.; Eason, James D.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Molnár, M, Nair, S, Cseprekal, O, Yazawa, M, Talwar, M, Balaraman, V, Podila, PSB, Mas, V, Maluf, D, Helmick, RA, Campos, L, Nezakatgoo, N, Eymard, C, Horton, P, Verma, R, Jenkins, AH, Handley, CR, Snyder, HS, Cummings, C, Agbim, UA, Maliakkal, B, Satapathy, SK & Eason, JD 2019, 'Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience', American Journal of Transplantation. https://doi.org/10.1111/ajt.15530
Molnár, M. ; Nair, Satheesh ; Cseprekal, Orsolya ; Yazawa, Masahiko ; Talwar, Manish ; Balaraman, Vasanthi ; Podila, Pradeep S.B. ; Mas, Valeria ; Maluf, Daniel ; Helmick, Ryan A. ; Campos, Luis ; Nezakatgoo, Nosratollah ; Eymard, Corey ; Horton, Peter ; Verma, Rajanshu ; Jenkins, Ann Holbrook ; Handley, Charlotte R. ; Snyder, Heather S. ; Cummings, Carolyn ; Agbim, Uchenna A. ; Maliakkal, Benedict ; Satapathy, Sanjaya K. ; Eason, James D. / Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients : Single center experience. In: American Journal of Transplantation. 2019.
@article{11f82d899f914fffb5ea494e86ad49ce,
title = "Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience",
abstract = "Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34{\%} were female, 19{\%} and 79{\%} of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81{\%}) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100{\%} were HCV RNA–negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2, respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients.",
keywords = "clinical research/practice, hepatitis C, infection and infectious agents - viral, kidney (allograft) function/dysfunction, kidney transplantation/nephrology",
author = "M. Moln{\'a}r and Satheesh Nair and Orsolya Cseprekal and Masahiko Yazawa and Manish Talwar and Vasanthi Balaraman and Podila, {Pradeep S.B.} and Valeria Mas and Daniel Maluf and Helmick, {Ryan A.} and Luis Campos and Nosratollah Nezakatgoo and Corey Eymard and Peter Horton and Rajanshu Verma and Jenkins, {Ann Holbrook} and Handley, {Charlotte R.} and Snyder, {Heather S.} and Carolyn Cummings and Agbim, {Uchenna A.} and Benedict Maliakkal and Satapathy, {Sanjaya K.} and Eason, {James D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15530",
language = "English",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients

T2 - Single center experience

AU - Molnár, M.

AU - Nair, Satheesh

AU - Cseprekal, Orsolya

AU - Yazawa, Masahiko

AU - Talwar, Manish

AU - Balaraman, Vasanthi

AU - Podila, Pradeep S.B.

AU - Mas, Valeria

AU - Maluf, Daniel

AU - Helmick, Ryan A.

AU - Campos, Luis

AU - Nezakatgoo, Nosratollah

AU - Eymard, Corey

AU - Horton, Peter

AU - Verma, Rajanshu

AU - Jenkins, Ann Holbrook

AU - Handley, Charlotte R.

AU - Snyder, Heather S.

AU - Cummings, Carolyn

AU - Agbim, Uchenna A.

AU - Maliakkal, Benedict

AU - Satapathy, Sanjaya K.

AU - Eason, James D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA–negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2, respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients.

AB - Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA–negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2, respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients.

KW - clinical research/practice

KW - hepatitis C

KW - infection and infectious agents - viral

KW - kidney (allograft) function/dysfunction

KW - kidney transplantation/nephrology

UR - http://www.scopus.com/inward/record.url?scp=85070087692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070087692&partnerID=8YFLogxK

U2 - 10.1111/ajt.15530

DO - 10.1111/ajt.15530

M3 - Article

C2 - 31306549

AN - SCOPUS:85070087692

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -